Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Avistone’s Met challenge
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
